GE HealthCare Technologies Inc. GEHC
Composite 46/100; the shares have moved about 40% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 34/100 — a moderate mark against it.
Valuation ranks 55/100 — a slight point in its favour.
Momentum ranks 34/100 — a moderate mark against it. Income ranks 35/100 — a moderate mark against it. Balance-sheet strength ranks 46/100 — a slight mark against it.
What the company does GE HealthCare Technologies Inc. designs, manufactures, and markets medical devices and digital solutions across imaging, advanced visualization, patient care, and pharmaceutical diagnostics. Its portfolio includes CT, MR, ultrasound, patient monitoring, and diagnostic agents used in screening, diagnosis, and treatment.
Key financials GEHC posts gross margins of 39.5% and net margins of 9.3%, with revenue growth of 5.8% and EPS growth of 16.8%. ROE is 19.4% and ROA is 5.1%, while debt/equity stands at 0.94 and net debt/EBITDA at 2.36. The current ratio is 1.26, and FCF yield is 4.7%.
Stock health Momentum is mixed: +14.99% over 3 months, -9.46% over 6 months, and -18.63% below the 52-week high. RSI(14) is 66.90, indicating near-term overbought conditions. Sideravia ranks overall quality as weak (45.9/100), with strength (42.6) and growth (36.0) trailing valuation (59.3).
Price vs fair value GEHC trades at a discount of 13.10% to the analyst mean target of 82.50. - Large-cap focus piece highlights GEHC among stocks with solid fundamentals (StockStory) - Barchart notes mixed analyst sentiment on GEHC’s near-term trajectory (Barchart)
Looking forward Forward P/E of 13.83 and PEG of 0.82 suggest valuation support, though growth (36.0) lags peers. Margin stability and FCF yield of 4.7% may underpin long-term value, but weak quality and momentum scores warrant caution.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.